Panorama

Who Needs to Care about Value Frameworks?

Public scrutiny on healthcare costs, particularly drug costs, has been mounting over the past ...

What Patients Really Want from AI in Healthcare

Lately, when people ask me about artificial intelligence and healthcare, I tend to talk ...

Taking a Super Bowl Approach to Medical Conferences

A funny thing happens when you talk “convention media.” People focus on how it ...

The Trouble with Sampling in the State of Ohio

Have you ever heard about Ohio’s Terminal Distributor of Dangerous Drugs (TDDD) licenses? Before ...

Next-Generation Forecasting Must Account for Payer Controls

The market access landscape for pharmaceutical products has shifted as payers struggle to control ...

How Drug Re-innovation Can Potentially Boost Pharma’s Depleting R&D Pipeline

The pharmaceutical industry’s typical R&D model of developing new chemical entities (NCEs) and creating ...

Transforming Hub Services and Increasing Speed to Therapy

In this final installment of a three-part series on integrating comprehensive hub services and ...

Trends that Emerged from J.P. Morgan Week 2018

Every January, tens of thousands of healthcare CEOs, investors, and business development executives descend ...

Best Practices for Forging Strategic Sponsor-CRO Relationships

A true strategic partnership has benefits for both the sponsor and the contract research ...